Literature DB >> 19075625

Mechanisms governing lentivirus integration site selection.

Angela Ciuffi1.   

Abstract

An essential step of the life cycle of retroviruses is the stable insertion of a copy of their DNA genome into the host cell genome, and lentiviruses are no exception. This integration step, catalyzed by the viral-encoded integrase, ensures long-term expression of the viral genes, thus allowing a productive viral replication and rendering retroviral vectors also attractive for the field of gene therapy. At the same time, this ability to integrate into the host genome raises safety concerns regarding the use of retroviral-based gene therapy vectors, due to the genomic locations of integration sites. The availability of the human genome sequence made possible the analysis of the integration site preferences, which revealed to be nonrandom and retrovirus-specific, i.e. all lentiviruses studied so far favor integration in active transcription units, while other retroviruses have a different integration site distribution. Several mechanisms have been proposed that may influence integration targeting, which include (i) chromatin accessibility, (ii) cell cycle effects, and (iii) tethering proteins. Recent data provide evidence that integration site selection can occur via a tethering mechanism, through the recruitment of the lentiviral integrase by the cellular LEDGF/p75 protein, both proteins being the two major players in lentiviral integration targeting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075625     DOI: 10.2174/156652308786848021

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  31 in total

Review 1.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

2.  LEDGF (p75) promotes DNA-end resection and homologous recombination.

Authors:  Mads Daugaard; Annika Baude; Kasper Fugger; Lou Klitgaard Povlsen; Halfdan Beck; Claus Storgaard Sørensen; Nikolaj H T Petersen; Poul H B Sorensen; Claudia Lukas; Jiri Bartek; Jiri Lukas; Mikkel Rohde; Marja Jäättelä
Journal:  Nat Struct Mol Biol       Date:  2012-07-08       Impact factor: 15.369

3.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

Review 4.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Targeting HIV-1 DNA integration by swapping tethers.

Authors:  Robert Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-09       Impact factor: 11.205

6.  Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach.

Authors:  Onur Tokgun; Francesco Paolo Fiorentino; Pervin Elvan Tokgun; Jun Yokota; Hakan Akca
Journal:  Mol Biotechnol       Date:  2017-06       Impact factor: 2.695

7.  The molecular biology of HIV integrase.

Authors:  Robert Craigie
Journal:  Future Virol       Date:  2012-07       Impact factor: 1.831

Review 8.  Towards systems tissue engineering: Elucidating the dynamics, spatial coordination, and individual cells driving emergent behaviors.

Authors:  Matthew S Hall; Joseph T Decker; Lonnie D Shea
Journal:  Biomaterials       Date:  2020-06-14       Impact factor: 12.479

Review 9.  Dynamic interactions between transposable elements and their hosts.

Authors:  Henry L Levin; John V Moran
Journal:  Nat Rev Genet       Date:  2011-08-18       Impact factor: 53.242

10.  Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein.

Authors:  Luciano Vozzolo; Belinda Loh; Paul J Gane; Maryame Tribak; Lihong Zhou; Ian Anderson; Elisabeth Nyakatura; Richard G Jenner; David Selwood; Ariberto Fassati
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.